CASI Pharmaceuticals, Inc. | License Agreements | Business Contracts

License and Development Agreement for CB-5339 by and between Cleave Therapeutics, Inc. and CASI Pharmaceuticals, Inc. dated March 5, 2021 (Filed With SEC on May 13, 2021)

License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc (Filed With SEC on March 30, 2021)

License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Spectrum Pharmaceuticals Cayman, L.P (Filed With SEC on March 30, 2021)

License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Talon Therapeutics, Inc (Filed With SEC on March 30, 2021)

Supplementary Agreement to the Exclusive License Agreement effective as of September 29, 2020 (Filed With SEC on November 9, 2020)

Exclusive License Agreement by and between CASI Pharmaceuticals, Inc. and Juventas Cell Therapy Ltd. effective June 15, 2019 (Filed With SEC on August 9, 2019)

CASI Pharmaceuticals, Inc. (43) | License Agreements (6)